Tailored antibody cures for HIV using AI and vaccines
Official title: MAATCH: Modeling Antibody Approaches for a Tailored Cure for HIV
Funded at Henry M. Jackson Fdn for the Adv Mil/med · NIH-11483233 · Data updated 2026-11-12
A study to design personalized antibody-based strategies to achieve HIV remission, using lab experiments and computer models to tailor vaccines or antibody treatments to individuals or small groups.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $1,744,119 |
| NIH project number | 1R01AI203702-01 |
| Project ID | NIH-11483233 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people living with HIV whose virus populations or disease characteristics could be matched to tailored antibody strategies.
✕Less likely to help
Patients with HIV strains or immune profiles not amenable to personalized antibody approaches may gain less or no benefit.
What this research studies
This project uses lab work and computer modeling to figure out how personalized an antibody-based cure for HIV needs to be. It explores three vaccine personalization levels and builds an AI tool to predict which antibodies will work best for a person’s virus. The goal is to guide development of B cell vaccines and antibody therapies that can lead to durable remission. The research could help clinicians decide when a fully personalized, semi-personalized, or group-based approach is most appropriate for a patient.
Why it matters
Potential benefit: If successful, this work could enable more effective, customized antibody therapies or vaccines that increase the likelihood of HIV remission.
How similar studies have gone: Previous work shows promise for antibody-based approaches, but this project directly integrates AI-driven personalization for HIV remission, which is innovative.
Where this research is happening
-
Henry M. Jackson Fdn for the Adv Mil/med
Bethesda, United States Active
Researchers
- Principal investigator: Trautmann, Lydie — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Trautmann, Lydie
Related research
Other NIH-funded projects on the same topics.
-
Cooperation partners of SETBP1 in AML development
This grant explores how SETBP1 and AF9 (MLLT3) work together to drive acute myeloid leukemia and whether targeting related epigenetic regulators could help treat aggressive CK-AML.
-
U.S. Military HIV Research Program Clinical Trials Unit expansion
A nationwide network of clinical trial sites is being expanded to test HIV prevention and treatment approaches through DAIDS-supported trials.
-
Novel protein biomarkers of chronic pain in adults using a pain registry biobank
A study in adults with chronic pain will look for new protein biomarkers in blood samples to understand better why pain persists and how to improve treatment.
-
Understanding how antibody protection works using 3D protein structures
Researchers will build a 3D-based method to see which viral features relate to prevention by antibodies, using data from people in HIV vaccine and monoclonal antibody trials.
-
Military HIV Clinical Network
This program runs HIV and TB prevention and treatment clinical studies for adults in military-associated and high-HIV-burden communities.
-
Military HIV Clinical Trials Unit
This program runs clinical trials of new HIV vaccines, prevention approaches, and TB treatments for adults at risk of or living with HIV.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.